Welcome to the final 2022 edition of the ADNeT newsletter.
I have just returned from San Francisco where I attended the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference. It is certainly an exciting time to be involved with dementia research, with many presenters feeling optimistic about the future of dementia research and treatments.
As we wrap up 2022, we share with you some of the achievements and highlights of ADNeT’s work over the year and that of our researchers, who have been recognised nationally and internationally for their work. We are also thrilled to be recognised as leading experts in dementia, with many of our researchers across ADNeT being requested to offer their insights on the new drug treatment, Lecanemab, in the media.
Please refer back to our news section for all the latest news and updates and we hope you enjoy this year’s final newsletter.
I wish you all a happy and restful holiday season and see you in the New Year.